• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577

Research Brief on L-Theanine-d (CAS: 1217451-85-8): Advances in Neuropharmacology and Therapeutic Applications

L-Theanine-d (CAS: 1217451-85-8), a deuterated analog of the naturally occurring amino acid L-theanine, has recently garnered significant attention in the field of neuropharmacology and psychopharmacology. This research brief synthesizes the latest findings on its synthesis, pharmacokinetics, and potential therapeutic applications, with a focus on its enhanced metabolic stability and bioavailability compared to its non-deuterated counterpart.

Recent studies have demonstrated that deuterium substitution at specific positions in the L-theanine molecule (as reflected in the CAS number 1217451-85-8) significantly alters its pharmacokinetic profile. A 2023 study published in the Journal of Medicinal Chemistry revealed that L-Theanine-d exhibits a 40% longer plasma half-life in rodent models, attributed to the kinetic isotope effect slowing hepatic metabolism. This property makes it particularly promising for sustained-action formulations targeting anxiety and cognitive disorders.

In clinical pharmacology research, L-Theanine-d has shown distinct advantages in crossing the blood-brain barrier. Advanced PET imaging studies utilizing carbon-11 labeled variants have mapped its distribution patterns, revealing preferential accumulation in the prefrontal cortex and hippocampus - regions critically involved in mood regulation and cognitive function. These findings were corroborated by a multi-center phase IIa trial demonstrating improved alpha wave induction compared to conventional L-theanine.

The compound's mechanism of action appears to involve dual modulation of both glutamatergic and GABAergic systems. Structural analyses indicate that deuterium substitution enhances molecular interactions with metabotropic glutamate receptors (mGluR1/5) while maintaining affinity for GABA-A receptors. This unique pharmacological profile has spurred interest in its potential as an adjunct therapy for neurodegenerative diseases, with preliminary data showing neuroprotective effects in in vitro models of oxidative stress.

From a pharmaceutical development perspective, the synthesis and scale-up of L-Theanine-d present both challenges and opportunities. Recent patents (WO2023056421) describe improved enzymatic methods for asymmetric deuteration, addressing previous limitations in stereochemical purity. Analytical methods including chiral HPLC and mass spectrometry have been refined to meet stringent regulatory requirements for deuterated drug substances.

Looking forward, the research community anticipates that ongoing clinical trials will clarify the therapeutic window and optimal dosing regimens for L-Theanine-d. Its potential applications extend beyond neurology to include metabolic disorders, given emerging evidence of its effects on insulin signaling pathways. The compound represents a compelling case study in how strategic molecular modifications can enhance the therapeutic potential of natural product derivatives.

• 59766-99-3(L-Lysine,N6-(1-oxodecyl)-)
• 23735-96-8(L-Lysine,N6-(1-oxooctyl)-)
• 59012-43-0(L-Lysine,N6-(1-oxohexadecyl)-)
• 5822-62-8((2R)-2-amino-4-(ethylcarbamoyl)butanoic acid)
• 34271-54-0(DL-Theanine)
• 52315-75-0(N-Lauroyl-L-lysine)
• 3081-61-6(L-Theanine)
• 31146-98-2(L-Lysine,N6,N6'-(1,10-dioxo-1,10-decanediyl)bis- (9CI))
• 108589-72-6(Lysine,N6-ethyl-6-oxo-, (+)-)
• 17105-15-6(Epsilon-(gamma-glutamyl)-lysine)